Idebenone: study protocols
21 study groups say how much Idebenone participants took a day. These are the doses the studies gave. They are not a recommendation.
Dose per serving from research
18 study groups in 14 studies say how much Idebenone participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 250 mg to 500 mg, 44% of 18 study groups.
| Daily dose | Study groups |
|---|---|
| 50 mg or less | 1 |
| 50 mg to 100 mg | 3 |
| 100 mg to 250 mg | 0 |
| 250 mg to 500 mg | 8 |
| 500 mg to 1 g | 6 |
Commonly used together
None of these 21 study groups took Idebenone with anything else.
21 study groups
| Study | |||
|---|---|---|---|
| Idebenone reduces respiratory complications in patients with Duchenne muscular dystrophy 2016 · idebenone group · Patients aged 10–18 years with Duchenne muscular dystrophy who were not taking concomitant glucocorticoid steroids | 900 mg | 1 year | 31 |
| Sustained efficacy and safety of idebenone in the treatment of Alzheimer's disease: update on a 2-year double-blind multicentre study 1998 · placebo for 12 months, followed by idebenone 90 mg tid for another 12 months · Patients with mild to moderate dementia of the Alzheimer type | 270 mg | 1 year | 153 |
| Sustained efficacy and safety of idebenone in the treatment of Alzheimer's disease: update on a 2-year double-blind multicentre study 1998 · idebenone 120 mg tid for 24 months · Patients with mild to moderate dementia of the Alzheimer type | 360 mg | 2 years | 149 |
| Sustained efficacy and safety of idebenone in the treatment of Alzheimer's disease: update on a 2-year double-blind multicentre study 1998 · idebenone 90 mg tid for 24 months · Patients with mild to moderate dementia of the Alzheimer type | 270 mg | 2 years | 148 |
| Safety and efficacy of idebenone versus tacrine in patients with Alzheimer's disease: results of a randomized, double-blind, parallel-group multicenter study 2002 · idebenone · Men and women aged 40–90 with mild-to-moderate dementia of the Alzheimer type | 360 mg | 60 weeks | 104 |
| A controlled study of 2 doses of idebenone in the treatment of Alzheimer's disease 1997 · idebenone 30 mg t.i.d. · Patients with mild to moderate dementia of the Alzheimer type | 90 mg | 26 weeks | 100 |
| A controlled study of 2 doses of idebenone in the treatment of Alzheimer's disease 1997 · idebenone 90 mg t.i.d. · Patients with mild to moderate dementia of the Alzheimer type | 270 mg | 26 weeks | 100 |
| A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy 2011 · Idebenone 900 mg/day · People aged 14–64 with Leber's hereditary optic neuropathy and one of the specified mitochondrial DNA mutations, with vision loss onset within 5 years; both sexes | 900 mg | 24 weeks | 55 |
| Idebenone in the treatment of multi-infarct dementia: a randomised, double-blind, placebo controlled multicentre trial 1992 · idebenone · Patients with mild-to-moderate multi-infarct dementia | 90 mg | 90 days | 52 |
| Effects of idebenone in elderly subjects with cognitive decline. Results of a multicentre clinical trial 1992 · idebenone · elderly patients with senile cognitive decline | 90 mg | — | 39 |
| Efficacy of idebenone on respiratory function in patients with Duchenne muscular dystrophy not using glucocorticoids (DELOS): a double-blind randomised placebo-controlled phase 3 trial 2015 · idebenone · Patients aged 10–18 years with Duchenne muscular dystrophy who were not taking concomitant glucocorticoids | 900 mg | 52 weeks | 32 |
| Treatment effect of idebenone on inspiratory function in patients with Duchenne muscular dystrophy 2017 · Idebenone · Patients aged 10–18 years with Duchenne muscular dystrophy, PEF percent predicted below 80%, and no glucocorticoid use during the study | 900 mg | 52 weeks | 31 |
| Home-Based Monitoring of Pulmonary Function in Patients with Duchenne Muscular Dystroph 2018 · Idebenone · Patients aged 10–18 years with Duchenne muscular dystrophy and pulmonary function decline (PEF% predicted ≤80%); off glucocorticoids for at least 1 year before enrolment | 900 mg | 52 weeks | 31 |
| Effects of idebenone on color vision in patients with leber hereditary optic neuropathy 2013 · idebenone · Patients with Leber hereditary optic neuropathy (LHON) caused by one of three primary mtDNA mutations, with vision loss within 5 years before enrolment; age range and sex not restricted | 900 mg | 24 weeks | 28 |
| Idebenone as a novel, therapeutic approach for Duchenne muscular dystrophy: results from a 12 month, double-blind, randomized placebo-controlled trial 2011 · idebenone · Children aged 8–16 years with Duchenne muscular dystrophy | 450 mg | 1 year | 13 |
| Randomized, double-blind, placebo controlled, multicentre study of idebenone in patients suffering from multi-infarct dementia 1992 · idebenone · Elderly patients with mild to moderate mental deterioration of vascular origin (multi-infarct dementia) | 45 mg | 120 days | — |
| Effects of glucocorticoids and idebenone on respiratory function in patients with duchenne muscular dystrophy 2013 · Idebenone, glucocorticoid-naïve patients · Boys aged 8–16 years with Duchenne muscular dystrophy who were glucocorticoid-naïve | 450 mg | 1 year | — |
| Effects of glucocorticoids and idebenone on respiratory function in patients with duchenne muscular dystrophy 2013 · Idebenone, patients receiving concomitant glucocorticoids · Boys aged 8–16 years with Duchenne muscular dystrophy receiving concomitant glucocorticoids | 450 mg | 1 year | — |
| Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial 2007 · approximately 5 mg/kg idebenone group · Patients aged 9–17 years with genetically confirmed Friedreich's ataxia | 5 mg/kg | 26 weeks | — |
| Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial 2007 · approximately 15 mg/kg idebenone group · Patients aged 9–17 years with genetically confirmed Friedreich's ataxia | 15 mg/kg | 26 weeks | — |
| Neurological effects of high-dose idebenone in patients with Friedreich's ataxia: a randomised, placebo-controlled trial 2007 · approximately 45 mg/kg idebenone group · Patients aged 9–17 years with genetically confirmed Friedreich's ataxia | 45 mg/kg | 26 weeks | — |